Dupilumab and tezepelumab in severe refractory asthma: new opportunities.
Ragnoli B, Morjaria J, Pignatti P, Montuschi P, Barbieri M, Mondini L, Ruggero L, Trotta L, Malerba M.
Ragnoli B, et al.
Ther Adv Chronic Dis. 2022 May 25;13:20406223221097327. doi: 10.1177/20406223221097327. eCollection 2022.
Ther Adv Chronic Dis. 2022.
PMID: 35655942
Free PMC article.
Review.